Skip to main content
Premium Trial:

Request an Annual Quote

Japanese NGS Firm Quantum Bio Raises $20M

NEW YORK(GenomeWeb) – Japanese next-generation sequencing technology firm Quantum Biosystems has raised ¥2.4 billion ($20 million) to continue development of its DNA/RNA sequencer.

The Series B funding comes from new investors Innovation Network Corporation of Japan and Mitsubishi UFJ Capital, as well as existing investors JAFCO, UTEC, and Mizuho Capital, the firm said. 

Founded in 2013 and based in Osaka, Quantum Bio is developing single-molecule electronic DNA sequencing technology. The technology measures tunneling currents from DNA bases as the molecule passes by a sub-nanometer gap. It relies on a pair of nanoelectrodes separated by a sub-nanometer gap, across which it places a bias voltage. It then detects changes in the tunneling current as single-stranded DNA or RNA translocates through the gap. 

Quantum Bio told GenomeWeb last year that it was developing a next-generation of the technology that uses a gating nanopore to confine the motion of translocating DNA. Its founders are Toshihiko Honkura, now Quantum Bio's president and CEO, and Masateru Taniguchi, the company's CSO.

The Scan

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.